

Ref: 11/SE/LC/2026-27

Date: May 28, 2026

Scrip Code BSE: 544122  
NSE: ENTERO  
ISIN: INE010601016

To,

**Head, Listing Compliance Department  
BSE Limited**

Phiroze Jeejeebhoy Towers Dalal Street,  
Mumbai - 400 001.

**Head, Listing Compliance Department  
National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1. G Block,  
Bandra -Kurla Complex, Bandra (East),  
Mumbai- 400051

Dear Sir/Madam,

**Subject: Clarification on Investor Queries relating to profit attributable to owners of the Company and minority interest for the Quarter ended 31<sup>st</sup> March 2026**

**Ref: Intimation no. 06/SE/LC/2026-27 dated May 25, 2026**

This is with reference to certain investor queries received by the Company in relation to the Financial Results for the Quarter ended 31<sup>st</sup> March 2026, particularly regarding:

1. Relatively modest growth in profit attributable to owners of the Company during the Quarter; and
2. Increase in non-controlling interest (minority interest).

In this regard, the Company wishes to provide the following clarifications for the benefit of stakeholders:

**1. Profit Attributable to Owners of the Company:**

While the Company reported operational growth during the quarter, the growth in profit attributable to owners of the Company was impacted by certain one-off items amounting to INR 114 million on account of costs associated with closure of a business contract and higher provisioning charges and write-offs. These items arose from Entero's Standalone Financials and its Wholly Owned Subsidiaries, affecting the profit attributable to the owners of the Company.

**2. Increase in Non-Controlling Interest:**

The increase in non-controlling interest during the quarter is primarily attributable to the acquisition of Anand Chemiceutics Private Limited done during the Quarter, in which the Company has acquired a 51.51% ownership stake.

Accordingly, a higher share of profits attributable to minority shareholders of such subsidiary has been reflected under non-controlling interest in the Consolidated Financial Statements.

The above clarification is being submitted to ensure transparency and adequate dissemination of information to investors.

Kindly take the same on record.

Yours Faithfully  
For **Entero Healthcare Solutions Limited**

Sanu Kapoor  
**Vice President- General Counsel, Company Secretary  
& Compliance Officer**